GlassScriptPhysician profile
Donna R Muresan
NPI 1912134495
$1,232.64
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $191 · 2023: $42.92 · 2024: $30.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.87 | 2021-2024 | |
| Boston Scientific Corporation | $299.01 | 2021 | |
| Abbott Laboratories | $141.75 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.44 | 2021 | |
| Scilex Pharmaceuticals INC. | $61.43 | 2021 | |
| Collegium Pharmaceutical, INC. | $59.47 | 2021 | |
| Biodelivery Sciences International, INC. | $48.15 | 2021 | |
| Amgen INC. | $47.54 | 2021 | |
| Pacira Therapeutics, INC. | $42.58 | 2021 | |
| Redhill Biopharma INC. | $37.27 | 2021 | |
| Nalu Medical, INC. | $31.52 | 2021 | |
| Tersera Therapeutics LLC | $22.38 | 2022 | |
| Lilly USA, LLC | $21.42 | 2021 | |
| Allergan, INC. | $18.65 | 2022 | |
| Uswm, LLC | $16.85 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $16.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Muresan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.